comparemela.com
Home
Live Updates
FDA Approves Secukinumab for Hidradenitis Suppurativa : comparemela.com
FDA Approves Secukinumab for Hidradenitis Suppurativa
Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.
Related Keywords
Smitht Alexa Kimball ,
Alexa Kimball ,
Jennifer Hsiao ,
Kunzmannk Jennifer Hsiao ,
Kunzmannk Matthew Zirwas ,
Novartis Cosentyx ,
Matthew Zirwas ,
Hidradenitis Suppurativa ,
Novartis ,
Drug Administration ,
Keck School Of Medicine ,
Hidradenitis Suppurativa Clinical Response ,
Keck School ,
Greater Columbus ,
Secukinumab Treatment ,
Published February ,
Published June ,
How Do Emerging ,
Dhs ,
Fda ,
Food And Drug Administration ,
Us Fda ,
Approval ,
Drugs ,
Secukinumab ,
Cosentyx ,
comparemela.com © 2020. All Rights Reserved.